Core Insights - LENZ Therapeutics is hosting a Commercial Day to discuss the commercialization strategy and progress towards the potential approval of LNZ100 for presbyopia treatment on April 15, 2025 [1][2] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first aceclidine-based eye drop for improving near vision in presbyopia patients [4] - LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, evaluated in the Phase 3 CLARITY study [4] - The condition of presbyopia affects approximately 1.8 billion people globally and 128 million in the United States [4] - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [4] Event Details - The Commercial Day will feature management presentations on commercialization strategies, supply chain readiness, and insights from Key Opinion Leaders and Eye Care Professionals [2] - A live audio webcast of the event will be available on the LENZ Therapeutics website, with a replay accessible for 12 months [3]
LENZ Therapeutics to Host Commercial Day on April 15, 2025